文献速递皮肤肿瘤

转移性皮肤黑色素瘤患者伊匹木单抗真实世界治疗模式与结局

Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-11-08

该回顾性多中心观察性研究纳入澳、德、意、西四国371例接受伊匹木单抗治疗的晚期黑色素瘤患者,评估治疗模式与结局。67%患者将伊匹木单抗作为二线或后续治疗,平均接受3.4剂。伊匹木单抗难治患者中接受后续治疗者死亡风险降低40%(HR 0.60;95%CI 0.43-0.83),但进展后总生存仍差。

要点

  • 伊匹木单抗在真实世界中主要作为二线或后续治疗使用。
  • 伊匹木单抗难治后接受后续治疗与死亡风险降低40%相关。
  • 伊匹木单抗进展后总生存仍差,亟需更有效的终末期治疗方案。

核心结论

  • 伊匹木单抗在观察期内主要作为二线或后续治疗,难治后接受后续治疗与死亡风险降低相关,但进展后总生存仍差。

研究设计与样本

  • 回顾性多中心、多国观察性病历回顾研究,纳入澳大利亚、德国、意大利和西班牙的371例晚期黑色素瘤患者。
  • 数据从伊匹木单抗治疗开始提取至至少40周随访结束或死亡。

主要发现

  • 371例患者中,澳大利亚103例、德国152例、意大利76例、西班牙40例;平均年龄65岁,62%为男性,94%的ECOG PS为0或1。
  • 67%的患者将伊匹木单抗作为二线或后续治疗,平均接受3.4剂。
  • 伊匹木单抗难治队列共226例,其中澳大利亚17%、德国47%、意大利29%、西班牙14%接受后续抗黑色素瘤治疗,包括26%化疗和11% BRAF/其他激酶抑制剂。
  • 伊匹木单抗难治后接受治疗者较未接受治疗者死亡风险降低40%(HR 0.60;95%CI 0.43-0.83),经潜在混杂因素调整。

临床怎么用

  • 真实世界中伊匹木单抗多用于二线或后续治疗,临床决策需结合治疗线数。
  • 伊匹木单抗难治后应考虑后续治疗,可能降低死亡风险。
  • 伊匹木单抗进展后总生存仍差,需关注终末期治疗选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a scarcity of real-world data on treatment patterns and outcomes among advanced melanoma patients treated with immunotherapies including ipilimumab, an anti-CTLA-4 antibody approved since 2011. OBJECTIVE: To evaluate ipilimumab and postipilimumab treatment patterns and outcomes among patients with advanced melanoma in Australia, Germany, Italy and Spain, following regulatory approval. METHODS: Retrospective multicentre, multinational, observational chart review study. Data were extracted from the start of ipilimumab therapy until the end of at least 40 weeks of follow-up, or death. RESULTS: Data from 371 patients (Australia, 103; Germany, 152; Italy, 76; Spain, 40) were analysed. Mean age was 65 years; 62% were male. Eastern Cooperative Oncology Group performance status (ECOG PS) was 0 or 1 for 94%. In 67%, ipilimumab was initially received as second-line or later therapy. Patients received on average 3.4 ipilimumab doses. The ipilimumab-refractory cohort comprised of 226 patients. Of these, 17% in Australia, 47% in Germany, 29% in Italy and 14% in Spain received another antimelanoma treatment after ipilimumab including chemotherapy in 26% and BRAF/other kinase inhibitors in 11%. Ipilimumab-refractory patients who received postipilimumab treatment showed a 40% reduced hazard of dying than those not receiving treatment after ipilimumab (HR 0.60; 95% CI 0.43-0.83), after adjustment for potential confounders. CONCLUSION: During the time observed, ipilimumab was mainly used as second-line or later therapy. A significant proportion of patients received postipilimumab therapy, most of which was chemotherapy. Nevertheless, overall survival following progression on ipilimumab treatment remained poor, highlighting the need for research to develop more effective end-of-life treatment options.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Mohr P, Ascierto P, Arance A, et al. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab. J Eur Acad Dermatol Venereol. 2017. PMID: 29044660. doi:10.1111/jdv.14633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。